Gross Product Sales was Rigel Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $309.96M of $294.28M (105%).
| Product and Service | FY 2016 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Product Sales | $108.52M | $147.06M | $209.92M | $309.96M | |||||
| Release Of Share Cost Liability | — | — | — | $39.98M | |||||
| Contract Revenues From Collaborations | — | — | — | — | |||||
| License Revenue | — | — | $14.00M | — | |||||
| License | $7.93M | — | — | — | |||||
| License Revenues | — | — | — | — | |||||
| Delivery Of Drug Supplies, Royalty & Others | $6.09M | $11.41M | $20.38M | $19.05M | |||||
| Milestone Revenue | — | $75.00K | — | $3.00M | |||||
| Milestone | $25.00M | — | — | — | |||||
| Development Milestones | — | — | — | — | |||||
| Government Contracts | $4.50M | $1.10M | — | $265.00K | |||||
| Research & Development Services And Others | — | — | — | — | |||||
| Research & Development Services | — | — | — | — | |||||
| Discounts & Allowances | -$31.81M | -$42.76M | -$65.02M | -$77.98M | |||||
| Total | $120.24M | $116.88M | $179.28M | $294.28M |
Rigel Pharmaceuticals brought in $294.28M from its six product and service lines in fiscal 2025, the year ended December 31, 2025. Rigel Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $179.28M. Gross Product Sales was the largest at $309.96M (105.3%), ahead of Release Of Share Cost Liability at $39.98M (13.6%) and Delivery Of Drug Supplies, Royalty & Others at $19.05M (6.5%). The other two lines brought in $3.27M combined.
Compared with fiscal 2024, Gross Product Sales grew 47.7% to $309.96M, while Delivery Of Drug Supplies, Royalty & Others fell 6.5% to $19.05M.
Rigel Pharmaceuticals began breaking out Release Of Share Cost Liability in fiscal 2025 and Milestone Revenue in fiscal 2023. Rigel Pharmaceuticals stopped reporting Milestone ($25.00M in fiscal 2022), License Revenue ($14.00M in fiscal 2024) and License ($7.93M in fiscal 2022) as separate lines. The total is net of Discounts & Allowances, which took $77.98M off revenue in fiscal 2025.
Rigel Pharmaceuticals (RIGL) reports its revenue by product and service. In fiscal 2025, Gross Product Sales was its largest product and service line, bringing in $309.96M (105.3% of the total), followed by Release Of Share Cost Liability at $39.98M (13.6%).
Gross Product Sales was Rigel Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $309.96M, or 105.3% of the $294.28M total across its six product and service lines.
Every figure comes from Rigel Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Rigel Pharmaceuticals gives it, and years follow its fiscal calendar.
Rigel Pharmaceuticals' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.